PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91025C00044Tumor-derived extracellular vesicles for — Fyr Diagnostics Inc

Fyr Diagnostics Inc holds $355K across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 55 offers. Set-aside status: SBA. Recompete timing centers on the Sep 14, 2026 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci

Awarding office

Fyr Diagnostics Inc

Recipient

Sep 14, 2026

PoP end

$355K

Obligated

$355K

Potential

541714

NAICS

AN12

PSC

SBA

Set-aside

55 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Fyr Diagnostics Inc — $90

Contract facts

SBA

Contract number75N91025C00044

AgencyNih Nci

Awarding officeNih Nci

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentFyr Diagnostics Inc

CAGE8KXG5

UEIFXC2KX47NS48

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12

Place of performanceMISSOULA MT

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

PoP startSep 15, 2025

PoP end (current)Sep 14, 2026

Obligated$355K

Current value$355K

Potential value$355K

TUMOR-DERIVED EXTRACELLULAR VESICLES FOR DIAGNOSIS OF EARLY-STAGE OVARIAN CANCER is a federal SBA award for Nih Nci held by Fyr Diagnostics Inc. Estimated value $355K ($355K obligated). Current period of performance ends Sep 14, 2026. Last award drew 55 bidders. Place of performance: MISSOULA MT.

TUMOR-DERIVED EXTRACELLULAR VESICLES FOR DIAGNOSIS OF EARLY-STAGE OVARIAN CANCER

Recompete timing

Public

● Expiring in 7 days

Current PoP ends Sep 14, 2026 (7 days remaining). Agencies typically plan 12–18 months ahead — at 0.2 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Fyr Diagnostics Inc — $355K obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$355K · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N91025C00044?

75N91025C00044 (Tumor-derived extracellular vesicles for) is a Nih Nci award with a potential value of $355K, currently held by Fyr Diagnostics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91025C00044?

Nih Nci awarded 75N91025C00044 to Fyr Diagnostics Inc (potential $355K).

Who is the incumbent on 75N91025C00044?

Fyr Diagnostics Inc is the incumbent with $355K across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 14, 2026.

When does Fyr Diagnostics Inc’s 75N91025C00044 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 14, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N91025C00044 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Sep 10, 2025